Skip to navigation Skip to content



About this Medication
  • Brand Name: Bafiertam™ (U.S.) (bah-feer-tam)
  • Chemical Name: monomethyl fumarate (mono-METH-il FOO-mah-rate)
  • Usage in MS: Disease-Modifying Agent
  • Generic Available: No

This is an oral medication in capsule form.

*Release of Bafiertam™: Bafiertam is not yet available for prescription. Details and cost will be provided when they become available.


Bafiertam is an oral therapy taken two times per day. Bafiertam is similar to Tecfidera® and Vumerity™ but has a distinct chemical structure. Although their exact mechanisms of action are not known, fumarate therapies are thought to modulate the immune response underlying MS to be less inflammatory, and may have antioxidant properties that could be protective against damage to the brain and spinal cord.

Bafiertam was approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Click here to read the Bafiertam Prescribing Information for healthcare professionals.

To read the medication guide (patient information), go to the FDA Prescribing Information and scroll down to page 18.


Banner Life Sciences

Financial Assistance Program

Financial assistance program information has not been released and will be published here when it is available.


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.